Login to Your Account



Clinic Roundup


Tuesday, October 4, 2011
Santaris Pharma A/S, of Horsholm, Denmark, reported data from a Phase IIa trial showing that miravirsen, a microRNA-targeted drug, provided continuous and prolonged antiviral activity well beyond the end of active therapy in hepatitis C virus patients and was well tolerated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription